NYSE : SOLV

Solventum Corporation

$78.6 USD

-$0.65 (-0.82%)

Volume
598.76K
Average Volume
1.67M
Market Capitalization
$13.61B
P/E Ratio
9.57
Dividend Yield
0.00%
Price Target
$90.50
Year High
$88.20
Year Low
$62.38
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$1.07
Company Overview

NYSE

Bryan C. Hanson

Medical - Care Facilities

Healthcare

SOLV

20000

US

USD

https://www.solventum.com

651-733-1110

83444M101

0001964738

Liquidity Metrics

1.02

1.07

0.75

0.17

0.00

Sales & Valuation

$8.32B

1.65

2.76

-67.05

-1.17

Profitability

$8.88

$1.56B

17.33%

20.47%

30.71%

10.16%

P/E Metrics

9.57

0.03

0.03

Analyst Price Target & Rating

$90.50

$94.00

$43.00

Buy

4/5

11 Analysts

-13.15%

Financial Health Scores

2.18

6/9

$237M

$14.1B

$9.13B

$2B

Key Metrics (TTM)

$18.24B

2.21

6.62

1.07

30.71%

15.87%

10.38%

-1.48%

$72.64

84 days

Company Executives
Name Title
Rachel H. Ellingson Chief Strategy & Corporate Development Officer
Tammy L. Gomez Chief Human Resources Officer
Bryan C. Hanson Chief Executive Officer & Director
Mike Spears Senior Vice President of Regulatory Affairs & Quality Assurance
Paul S. Harrington Chief Supply Chain Officer
Wayde D. McMillan Executive VP & CFO
Amy Landucci Chief Information & Digital Officer
Amy Wakeham Senior Vice President of Investor Relations & External Finance Communications
Garri Garrison President of Health Information Systems
Heather L. Knight Chief Commercial Officer
Kate Dobbs Chief Communications & Corporate Marketing Officer
Marcela A. Kirberger Chief Corporate & Legal Affairs Officer & Corporate Secretary
Mary T. Wilcox Senior Vice President, Corporate Controller & Chief Accounting Officer
Poll Results

No votes yet today — be the first to share your view!

About Solventum Corporation (NYSE:SOLV) Stock

Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.V.) site management tools, sterilization assurance systems, temperature regulation devices, surgical instruments, stethoscopes, and medical electrodes. Its Dental Solutions segment provides a comprehensive range of dental and orthodontic offerings, such as brackets, clear aligners, restorative filling materials, and bonding agents. The Health Info ... rmation Systems division concentrates on advanced software platforms, covering functionalities like computer-assisted physician documentation, direct billing and coding automation, classification frameworks, voice recognition capabilities, and data visualization tools. Finally, the Purification and Filtration segment supplies an array of purification and filtration technologies, including various filters, purifiers, cartridges, and specialized membranes.

Earnings Growth & Price Strength Make Solventum (SOLV) a Stock to Watch

2026-07-16 10:36:18

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.

Solventum to Report Second Quarter Fiscal 2026 Earnings on August 5, 2026

2026-07-15 16:05:00

EAGAN, Minn., July 15, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its second quarter fiscal 2026 financial results on Wednesday, August 5, 2026, after the U.S. financial markets close.

Solving A Lackluster Growth Outlook Should Be Solventum's Next Priority

2026-07-10 11:03:48

Solventum Corporation continues to trade at a noticeable discount, with shares showing resilience versus med-tech peers despite tepid growth expectations. Management targets 3–4% underlying revenue growth for 2026, with SOLV EPS likely at the high end of the $6.40–$6.60 range. Restructuring and portfolio optimization offer significant upside, as SOLV's business units lack natural synergies and could be divested.

SOLV Energy: The Pullback Makes The Buy Case Stronger

2026-06-25 13:20:40

SOLV Energy remains a Buy as the backlog converts into higher-margin earnings, and the stock trades at a compelling valuation discount. MWH's $8.2B backlog and 1.2x book-to-bill offer strong near-term revenue visibility, with O&M and lifecycle services expanding long-term runway. The RWE acquisition strengthens MWH's grid-adjacent capabilities, enabling deeper customer relationships and a greater share of project spend.

Why Solventum (SOLV) is a Top Stock for the Long-Term

2026-06-25 10:31:09

The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

Earnings Growth & Price Strength Make Solventum (SOLV) a Stock to Watch

2026-06-09 10:31:14

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.

Solventum Trends for 2026: AI Coding, Tariffs, and Margins

2026-06-08 14:35:14

SOLV heads into 2026 balancing AI coding growth, cost savings, tariff pressure and a potential 2027 margin risk tied to its 3M supply deal.

SOLV Energy Announces Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares of Class A Common Stock

2026-06-04 17:18:00

SAN DIEGO, June 04, 2026 (GLOBE NEWSWIRE) -- SOLV Energy, Inc. (“SOLV” or the “Company”) (Nasdaq: MWH), a leading provider of infrastructure services to the power industry, today announced that, in connection with its previously completed public offering of 15,000,000 shares of Class A common stock of the Company, including 7,698,410 shares being offered by affiliates of American Securities LLC (the “Selling Stockholders”) and 7,301,590 shares being offered by the Company, the underwriters have fully exercised their option to purchase an additional 2,250,000 shares of Class A common stock of the Company, including 1,154,760 shares from the Selling Stockholders and 1,095,240 from the Company at the public offering price of $36.00 per share, less underwriting discounts and commissions. The issuance and sale of the additional shares closed today.

Frequently Asked Questions

What is the current Solventum Corporation (SOLV) stock price?

Solventum Corporation(NYSE:SOLV) stock price is $78.6 in the last trading session. During the trading session, SOLV stock reached the peak price of $88.2 while $62.38 was the lowest point it dropped to. The percentage change in SOLV stock occurred in the recent session was --0.82% while the dollar amount for the price change in SOLV stock was -$0.65.

SOLV's industry and sector of operation?

The NYSE listed SOLV is part of Medical - Care Facilities industry that operates in the broader Healthcare sector.

Who are the executives of SOLV?

Rachel H. Ellingson | Chief Strategy & Corporate Development Officer
Tammy L. Gomez | Chief Human Resources Officer
Bryan C. Hanson | Chief Executive Officer & Director
Mike Spears | Senior Vice President of Regulatory Affairs & Quality Assurance
Paul S. Harrington | Chief Supply Chain Officer

How many employees does SOLV have?

Number of SOLV employees currently stands at 20000. SOLV operates from 3M Center, Maplewood, MN 55144, US.

Link for SOLV official website?

Official Website of SOLV is: https://www.solventum.com

How do I contact SOLV?

SOLV could be contacted at phone #651-733-1110 and can also be accessed through its website. SOLV operates from 3M Center, Maplewood, MN 55144, US.

How many shares of SOLV are traded daily?

The average number of SOLV shares traded daily for last 3 months was 1.67M.

What is the market cap of SOLV currently?

The market value of SOLV currently stands at $13.61B with its latest stock price at $78.6